Results 31 to 40 of about 5,286 (232)

Bruton tyrosine kinase inhibitors for multiple sclerosis

Nature Reviews Neurology, 2023
Current therapies for multiple sclerosis (MS) reduce both relapses and relapse-associated worsening of disability, which is assumed to be mainly associated with transient infiltration of peripheral immune cells into the central nervous system (CNS). However, approved therapies are less effective at slowing disability accumulation in patients with MS ...
Julia Krämer, Amit Bar-Or, Timothy J. Turner, Heinz Wiendl   +3 more
openaire   +2 more sources

Bruton's tyrosine kinase: oncotarget in myeloma

Oncotarget, 2012
Our findings therefore provide a strong rationale for investigating Btk inhibitors in MM and WM to target both tumor cells and their supporting BM microenvironment and thereby both suppress tumor cell growth and abrogate MM-induced bone disease.
Yu-Tzu, Tai, Kenneth C, Anderson
openaire   +3 more sources

The new small tyrosine kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs

Haematologica, 2019
Tyrosine kinases have been implicated in promoting tumorigenesis of several human cancers. Exploiting these vulnerabilities has been shown to be an effective anti-tumor strategy as demonstrated for example by the Bruton's tyrosine kinase (BTK) inhibitor,
Debora Soncini, Stefania Orecchioni, Samantha Ruberti, Paola Minetto, Claudia Martinuzzi, Luca Agnelli, Katia Todoerti, Antonia Cagnetta, Maurizio Miglino, Marino Clavio, Paola Contini, Riccardo Varaldo, Micaela Bergamaschi, Fabio Guolo, Mario Passalacqua, Alessio Nencioni, Fiammetta Monacelli, Marco Gobbi, Antonino Neri, Giovanni Abbadessa, Sudharshan Eathiraj, Brian Schwartz, Francesco Bertolini, Roberto M. Lemoli, Michele Cea   +24 more
doaj   +1 more source

Second-generation inhibitors of Bruton tyrosine kinase [PDF]

Journal of Hematology & Oncology, 2016
Bruton tyrosine kinase (BTK) is a critical effector molecule for B cell development and plays a major role in lymphoma genesis. Ibrutinib is the first-generation BTK inhibitor. Ibrutinib has off-target effects on EGFR, ITK, and Tec family kinases, which explains the untoward effects of ibrutinib. Resistance to ibrutinib was also reported.
Jingjing Wu, Christina Liu, Stella T. Tsui, Delong Liu   +3 more
openaire   +3 more sources

Enhancing intracellular accumulation and target engagement of PROTACs with reversible covalent chemistry

Nature Communications, 2020
PROTACs have emerged as promising therapeutic agents but their cellular uptake is often inefficient. Here, the authors show that reversible covalent warhead chemistry improves PROTAC intracellular accumulation and target engagement, and develop a dual ...
Wen-Hao Guo, Xiaoli Qi, Xin Yu, Yang Liu, Chan-I Chung, Fang Bai, Xingcheng Lin, Dong Lu, Lingfei Wang, Jianwei Chen, Lynn Hsiao Su, Krystle J. Nomie, Feng Li, Meng C. Wang, Xiaokun Shu, José N. Onuchic, Jennifer A. Woyach, Michael L. Wang, Jin Wang   +18 more
doaj   +1 more source

Disseminated Cryptococcal Disease in a Patient with Chronic Lymphocytic Leukemia on Ibrutinib

Case Reports in Infectious Diseases, 2016
Cryptococcus is a unique environmental fungus that can cause disease most often in immunocompromised individuals with defective cell-mediated immunity. Chronic lymphocytic leukemia (CLL) is not known to be a risk factor for cryptococcal disease although ...
Koh Okamoto, Laurie A. Proia, Patricia L. Demarais   +2 more
doaj   +1 more source

Bruton’s tyrosine kinase inhibitor associated localized extremity edema and erythema [PDF]

JAAD Case Reports
Shannon Meledathu, BS, Paul Chu, MD, Tatyana Feldman, MD, Andre Henri Goy, MD, Rachel Kushner Rosenstein, MD, PhD   +4 more
doaj   +2 more sources

Single cell imaging of Bruton's Tyrosine Kinase using an irreversible inhibitor [PDF]

, 2014
A number of Bruton's tyrosine kinase (BTK) inhibitors are currently in development, yet it has been difficult to visualize BTK expression and pharmacological inhibition in vivo in real time.
Kim, Eunha, Weissleder, Ralph, Kohler, Rainer, Turetsky, Anna, Miller, Miles   +4 more
core   +1 more source

Efficacy and Safety of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia: Retrospective Analysis of Real-Life Data

Turkish Journal of Hematology, 2021
Objective: This study aimed to retrospectively evaluate the efficacy, safety, and survival outcome of single-agent ibrutinib therapy in chronic lymphocytic leukemia patients. Materials and Methods: A total of 136 patients (mean age +- standard deviation:
Anıl Tombak, Funda Pepedil Tanrıkulu, Salih Sertaç Durusoy, Hüseyin Derya Dinçyürek, Emin Kaya, Elif Gülsüm Ümit, İrfan Yavaşoğlu, Özgür Mehtap, Burak Deveci, Mehmet Ali Özcan, Hatice Terzi, Müfide Okay, Nilgün Sayınalp, Mehmet Yılmaz, Vahap Okan, Alperen Kızıklı, Ömer Özcan, Güven Çetin, Sinan Demircioğlu, İsmet Aydoğdu, Güray Saydam, Eren Arslan Davulcu, Gül İlhan, Mehmet Ali Uçar, Gülsüm Özet, Seval Akpınar, Burhan Turgut, İlhami Berber, Erdal Kurtoğlu, Mehmet Sönmez, Derya Selim Batur, Rahşan Yıldırım, Vildan Özkocaman, Ahmet Kürşad Güneş, Birsen Sahip, Şehmus Ertop, Olga Meltem Akay, Abdülkadir Baştürk, Mehmet Hilmi Doğu, Aydan Akdeniz, Ali Ünal, Ahmet Seyhanlı, Emel Gürkan, Demet Çekdemir, Burhan Ferhanoğlu   +44 more
doaj   +1 more source

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny

British Journal of Pharmacology
AbstractBruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B‐cell proliferative disorders. An impressive programme of drug discovery and clinical development led to the approval of covalent and non‐covalent Btk inhibitors that became pillars of treatment of such ...
Minotti, Giorgio, Camilli, Massimiliano, Salvatorelli, Emanuela, Menna, Pierantonio   +3 more
openaire   +3 more sources